PharmaNutra S.p.A. · MIL:PHN
PharmaNutra — H1 2023 Earnings Presentation
23 slides from PharmaNutra's earnings presentation, Sep 11, 2023
Slide 1: H1 2023 Financial Results
H1_2023 FINANCIAL RESULTS September 11th, 2023
Slide 2: Disclaimer
2 DISCLAIMER This document has been prepared by Pharmanutra S.p.A. (the “Company”) for use during meetings with investors and financial analyst and is solely for information purposes. It contains solely data and information provided by the Company or already in the public domain. This Document may n
Slide 3: Group Presentation & Highlights 2023
GROUP PRESENTATION & HIGHLIGHTS 2023
Slide 4: PharmaNutra Group
4 PHARMANUTRA 2023 GROUP Distribution of Cetilar® and Cetilar® Nutrition lines Distribution of Cetilar® and other main goup products PharmaNutra holds 100% of 2022 Junia Pharma, Alesco and Akern. Research and development of bioimpedance medical devices Just three years after the listing and software
Slide 5: Highlights H1 2023
5 HIGHLIGHTS H1 2023 § Launch of the new line of products dedicated to sports nutrition: Cetilar® Nutrition, a truly innovative line of products developed thanks to the application of Sucrosomial® Technology. § Establishment of Pharmanutra España § Signing of new distribution agreements for the dist
Slide 6: Highlights H1 2023
6 HIGHLIGHTS H1 2023 § New partnership with Ferrari-AF Corse; Cetilar® brand is present on the two official Ferrari 499P prototypes participating in the WEC championship. § New partnership with the spanish driver Fernando Alonso as a testimonial of Cetilar® Brand § Accounting of accrual of € 2 milli
Slide 7: Economic and Financial Data
7 ECONOMIC AND FINANCIAL DATA
Slide 8: Highlights H1 2023
8 HIGHLIGHTS H1 2023 NET REVENUES € 49,6 M § 25% Increase in Net Sales Revenues + 25% (+25% COMPARE TO H1 2022) § 13,2% EBITDA Growth § 28,3% EBITDA Margin on Revenues EBITDA € 14 M +13,2% (28,3% MARGIN ON REVENUES) § +12,8% Net Result excl. non-recurring items * § -12% Net Result § EPS excl. non-re
Slide 9: P&L KPI per New Project
9 P&L KPI PER NEW PROJECT 2023 PHN AS 2023 TOTAL ∆ 2023 PHN Amounts (€/000) NUTRITION CINA AKN ESPANA USA 2022 IS GROUP AS IS/2022 Net Sales Revenues 46.698 84 153 2.691 6 0 49.632 39.711 17,6% Operating expenses 32.139 743 237 1.634 298 528 35.578 27.296 17,7% EBITDA 14.559 (658) (84) 1.057 (292) (
Slide 10: Net Revenues
10 NET REVENUES Net revenues at 30.06.2023 accounted for € 49.6 million, recording a growth of 25% compared to the previous year. Revenues on domestic market grew by 22,6% while revenues on the foreign market recorded a growth of 31,5%. Akern’s net revenues accounted for € 2,7 million, about 5,4% on
Slide 11: Profit and Loss
11 PROFIT AND LOSS PHN GROUP PROFIT AND LOSS (€/000) 30/06/2023 30/06/2022 REVENUES Consolidated revenues accounted for € 49,6 million with an increase of 25% compared to the same period of the previous year. The increase is A) REVENUES 50.247 39.930 mainly driven from the growth in sales volume. Ne
Slide 12: Reclassified Consolidated Balance Sheet
12 RECLASSIFIED CONSOLIDATED BALANCE SHEET Amounts in €/000 30/06/2023 31/12/2022 ∆ 2023 vs 2022 Operating Working Capital Trade receivables 24.654 21.647 3.007 The increase in trade receivables is due to higher revenues. Inventories 7.338 5.261 2.077 The increase in inventories refers to the implem
Slide 13: Consolidated Cash Flow
13 CONSOLIDATED CASH FLOW Cash Flow (€/000) Net Result 30/06/2023 7.232 30/06/2022 8.232 CASH FROM OPERATING ACTIVITIES NON MONETARY EXPENSES Change in operating working capital Amortization, depreciation and w.o. 854 594 Increase in trade receivables due to higher revenues and sales volumes. Accrua
Slide 14: Net Financial Position
14 NET FINANCIAL POSITION NFP The negative Net Financial Position at 30.06.2023 accounted for € 10 million. The decrease compared to 31.12.2022 is mainly due to capital expenditures related to the construction of the new Headquarter and other operating capex (€ 9,7 million), to the purchases of trea
Slide 15: Market
=r us MARKET @PHARMANUTRA - a = | oe
Slide 16: Trend IMS & OD
16 Trend IMS & OD Quarterly Average Source IQVIA
Slide 17: Iron Supplements SiderAL Market Share in Italy
17 IRON SUPPLEMENTS SIDERAL® MARKET SHARE IN ITALY Excluding products that contain only lactoferrin Source IQVIA
Slide 18: Anti-Inflammatory Topical Cream Cetilar Market Share in Italy
18 ANTI-INFLAMMATORY TOPICAL CREAM CETILAR® MARKET SHARE IN ITALY Source IQVIA Source IQVIA
Slide 19: Apportal Compared to the Reference Markets
19 APPORTAL® COMPARED TO THE REFERENCE MARKETS Source IQVIA
Slide 20: International Development
20 INTERNATIONAL DEVELOPMENT New distribution contracts signed: Mexico, Indonesia, Kuwait, Benelux, Chile and Uruguay and Central America COUNTRIES PARTNERS Contracts 85 50 Active Sales 58 42 On-going Registration 27 8 On-going Negotiation 4 5
Slide 21: Outlook 2023
OUTLOOK 2023 @MPHARMANUTRA pes
Slide 22: Outlook 2023
22 OUTLOOK 2023 § The Group's existing business foresees a high double-digit organic growth trend in terms of revenues driven from sales on foreign markets. EBITDA is estimated in line with 2022 (29%). § Investments related to the new projects (Cetilar Nutrition, PHN ESP, PHN USA and China) are esti
Slide 23: @Pharmanutra
@PHARMANUTRA 2am seeversary